Bagel J, Armstrong A, Warren R, Papp K, Thaçi D, Menter A, Cather J, Augustin M, Hippeli L, Daamen C, Griffiths C. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial. J of Skin [Internet]. 2022Nov.16 [cited 2024Sep.20];6(6):s47. Available from: https://dermsquared.com/skin/article/view/1802